Literature DB >> 17701582

Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures.

Maria E Cabanillas1, Huifang Lu, Shenying Fang, Xianglin L Du.   

Abstract

To determine risk of osteoporosis and fractures associated with chemotherapy among elderly non-Hodgkin's lymphoma (NHL) patients, a cohort of 13 570 patients aged >/=65 years with incident NHL was identified from SEER-Medicare data with up to 11 years of follow-up. One year prior to the diagnosis, significantly fewer patients had fracture and osteoporosis claims in the chemotherapy group versus no chemotherapy group. However, after NHL diagnosis, patients who received chemotherapy had significantly higher rates of fracture (31% versus 19%, P < 0.001) and osteoporosis (10% versus 8%, P < 0.001), compared with those who did not. The risk of having fracture (odds ratio = 2.24, 95% CI = 2.04 - 2.45) and osteoporosis (odds ratio = 1.27, 95% CI = 1.12 - 1.45) was significantly higher in patients receiving chemotherapy compared with those who did not, after controlling for demographic and tumor factors. In conclusion, use of chemotherapy was significantly associated with increased risk of fracture and osteoporosis in elderly patients with NHL.

Entities:  

Mesh:

Year:  2007        PMID: 17701582     DOI: 10.1080/10428190701471973

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  11 in total

1.  Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

Authors:  Jason R Westin; Michael A Thompson; Vince D Cataldo; Luis E Fayad; Nathan Fowler; Michelle A Fanale; Saatva Neelapu; Felipe Samaniego; Jorge Romaguera; Jatin Shah; Peter McLaughlin; Barbara Pro; Larry W Kwak; Perpetua Sanjorjo; William A Murphy; Camillo Jimenez; Bela Toth; Wenli Dong; Fredrick B Hagemeister
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

Review 2.  Cancer therapies and bone health.

Authors:  Mimi I Hu; Huifang Lu; Robert F Gagel
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

3.  Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.

Authors:  Jennifer H Jordan; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Terry S Field; Reina Haque; Pamala A Pawloski; Hans V Petersen; Marianne N Prout; Virginia P Quinn; Marianne Ulcickas Yood; Rebecca A Silliman; Ann M Geiger
Journal:  Breast Cancer Res Treat       Date:  2014-06-18       Impact factor: 4.872

4.  Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.

Authors:  Stephen Booth; Hannah Plaschkes; Amy A Kirkwood; Adam Gibb; Patrick Horgan; Claire Higham; Joanna M Oladipo; Joe Browning; Usman Khan; Bing Tseu; Lucia Chen; John Willan; Julia Wolf; Arief Gunawan; Paul Fields; Tim Ebsworth; Robert Lown; Dominic Gordon-Walker; Nimish Shah; Kim M Linton; Graham P Collins; Jaimal Kothari; Catherine Hildyard; Toby A Eyre
Journal:  Blood Adv       Date:  2020-09-22

5.  High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas.

Authors:  Li-Wen Huang; Dong Sun; Thomas M Link; Thomas Lang; Weiyun Ai; Lawrence D Kaplan; Michael A Steinman; Charalambos Andreadis
Journal:  Support Care Cancer       Date:  2021-03-10       Impact factor: 3.603

6.  Impact of denosumab on bone mass in cancer patients.

Authors:  Ursa Brown-Glaberman; Alison T Stopeck
Journal:  Clin Pharmacol       Date:  2013-07-04

7.  Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study.

Authors:  Konstantinos Anargyrou; Despina Fotiou; Theodoros P Vassilakopoulos; Dimitrios Christoulas; Polyzois Makras; Maria Dimou; Ioannis Ntanasis-Stathopoulos; Stavroula Masouridou; Maria K Angelopoulou; Athanasios Papatheodorou; Konstantinos Tsionos; Panayiotis Panayiotidis; Meletios A Dimopoulos; Evangelos Terpos
Journal:  Hemasphere       Date:  2019-09-24

Review 8.  Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi.

Authors:  Sergio Di Molfetta; Antonella Daniele; Chiara Gerardi; Eleonora Allocati; Carla Minoia; Giacomo Loseto; Francesco Giorgino; Attilio Guarini; Vitaliana De Sanctis
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

9.  A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment.

Authors:  Paw Jensen; Lasse Hjort Jakobsen; Martin Bøgsted; Joachim Baech; Simon Lykkeboe; Marianne Tang Severinsen; Peter Vestergaard; Tarec Christoffer El-Galaly
Journal:  Blood Adv       Date:  2022-04-26

10.  Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures.

Authors:  J Bodden; D Sun; G B Joseph; L-W Huang; C Andreadis; M Hughes-Fulford; T F Lang; T M Link
Journal:  Osteoporos Int       Date:  2020-08-15       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.